Catalyst Biosciences Inc (CBIO)

NASDAQ
Currency in USD
Disclaimer
0.4823
-0.0077
(-1.57%)
Closed
High dividend Yield
Day's Range
0.4730
0.5000
52 wk Range
0.1887
0.7400
Volume
119,508
Prev. Close
0.49
Open
0.5
Day's Range
0.473-0.5
52 wk Range
0.1887-0.74
Volume
119,508
Average Vol. (3m)
396,597
1-Year Change
-6.13%
Shares Outstanding
37,974,892
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

People Also Watch

1.250
CREG
-
10.4400
AXLA
-1.23%
0.5573
RETO
+2.37%
0.1439
GLG
+1.62%
How do you feel today about CBIO?
Vote to see community's results!
or

Catalyst Biosciences Inc Company Profile

Catalyst Biosciences, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of Hydronidone for the treatment of nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease in the United States. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the United States and generated pharmacokinetic (PK), safety and tolerability data of single and multiple ascending doses of Hydronidone in United States healthy subjects. Hydronidone is a structural analogue of the approved anti-fibrotic (pulmonary fibrosis) drug pirfenidone. Hydronidone has been shown to inhibit both p38y kinase activity and TGF-b1- induced excessive collagen synthesis in vitro in hepatic stellate cells (HSCs), which are recognized as critical events in the development and progression of fibrosis in the liver.

Income Statement